Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
(
1 selected
)
Type
Guidance (294)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (5)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 221 to 230 of 294
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237
Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Technology appraisal guidance
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042
Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]
Technology appraisal guidance
Seladelpar for previously treated primary biliary cirrhosis ID 6429
Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458
Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)
Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995
Technology appraisal guidance
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827
Technology appraisal guidance
Previous page
1
…
21
22
Current page
23
24
25
…
30
Page
23
of
30
Next page
Results per page
10
25
50
All
Back to top